EUVIMED · CrossrefJournal
Journal of Market Access & Health Policy
ISSN 2001-6689 · MDPI AG
Latest articles
Per-Patient Medical Costs of Hemodialysis and Peritoneal Dialysis in Japan
Target Population Estimation in German Orphan Drug HTA: Trends and Differences in Epidemiological Data Sources
Operational Insights into Hospital Drug Inventory Control Through an Integrated ABC-VEN and Minimum–Maximum Stock Level Approach
Dialysis-Related Medical Expenditures of Hemodialysis and Peritoneal Dialysis in Japan
Dynamic Medicine Prices for Health-Economic Analyses in the Netherlands: A Case for Integrating Pre- and Post-Exclusivity Price Dynamics
From Joint Clinical Assessment to National Decisions: EU HTA Implementation and Implications for Patient Access
Health-Related Quality of Life of Patients with Epidermolysis bullosa and Carers Using a Time Trade-Off Approach in the UK General Population to Elicit Utilities for Health Technology Assessment
Treatment Preferences in Acute Allergic Reactions—How Can the Context Impact the Preference for a Corticosteroid Mouth Film Versus Conventional Tablets?
Valuation of Medical Innovation in Orphan Diseases with a Focus on Small Investors and Limited Diversifiable Risks
Guidance on Multiplicity Analysis in Single-Trial Assessments: A No-Solution Equation
The European Union’s Health Technology Assessment Regulation (EU-HTA R) Will Prosper Despite Major Setbacks
Multi-Criteria Decision-Making Framework for Sustainable Innovation Management in the Mexican Medical Device Manufacturing Industry: An Exploratory and Interdisciplinary Analysis
Analysis of How the Term “Shall” Is Understood and Applied to the EU-HTA Regulation
A Real-World Clinical Trial Evaluating Satisfaction and Experiences with a Dexamethasone Mouth Film Compared to Corticosteroid Tablets as Rescue Medication for Moderate to Severe Acute Allergic Reactions
Epistemological Tensions in the EU HTA Joint Clinical Assessment: The Illusion of Judgment-Free Evaluation
Market Care and Custody: A Health Policy Analysis of Incarceration and Long-Term Care Systems in the U.S.
The EU-Joint Clinical Assessment Guidance Documents Fail to Address the Significance of Systematic Literature Reviews and Deviate from the State of the Art
Supporting the Implementation and Addressing the Challenges of the EU HTA Regulation
Operative Costs and Anesthesia Exposure Time for Pediatric Glaucoma Surgeries
A Decision Tree Cost Analysis of Intracranial Bleed Detection Using a Near-Infrared Device Across Various Healthcare Levels
Use of Real-World Evidence in Health Technology Assessments of Non-Oncology Rare Disease Therapies
EU-HTA—Why Do Words Matter?
Between Rigor and Relevance: Why the EU HTA Guidelines on Indirect Comparisons Miss the Mark
Impact of a Digital Leakage Notification System on Healthcare Resource Utilisation and Costs for People with Stomas in the United Kingdom: Analysis of Interim Results from a Prospective Longitudinal Study
Primary Care or Primary Problem? Aligning Access Pathways with Patient Needs Across the Care Continuum
Introducing an Expanded Value Framework in Health Technology Assessment of Vaccines
When Do Annuity-Based Payments Help to Address the Affordability Challenge of Funding Advanced Therapies? Insights from a Budget Impact Simulation
Household Out-of-Pocket Burden Costs for Pediatric Pneumonia in Low- and Middle-Income Countries: Evidence Review and Econometric Framework
Accessibility of Biologic Drugs in Morocco: Comparison with FDA and EMA Approvals (2015–2025)
Mapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for Harmonization
EUVIMED